MCID: BRN015
MIFTS: 42

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 12 14
Minimally Invasive Lung Adenocarcinoma 12
Adenocarcinoma, Bronchiolo-Alveolar 42
Bronchioloalveolar Adenocarcinoma 69
Bronchioalveolar Lung Carcinoma 12
Bronchioloalveolar Carcinoma 12
Carcinoma Bronchioloalveolar 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4926
MeSH 42 D002282
NCIt 47 C2923
UMLS 69 C0007120

Summaries for Bronchiolo-Alveolar Adenocarcinoma

Disease Ontology : 12 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary : Bronchiolo-Alveolar Adenocarcinoma, also known as minimally invasive lung adenocarcinoma, is related to mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma and mucinous bronchioloalveolar adenocarcinoma, and has symptoms including coughing, dyspnea and fever. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Bladder cancer and Central carbon metabolism in cancer. The drugs Gefitinib and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
id Related Disease Score Top Affiliating Genes
1 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.2
2 mucinous bronchioloalveolar adenocarcinoma 11.2
3 nonmucinous bronchioloalveolar adenocarcinoma 11.2
4 extragonadal nonseminomatous germ cell tumor 10.4 EGFR NKX2-1
5 adenocarcinoma 10.4
6 caroli disease 10.4 EGFR NKX2-1
7 kidney benign neoplasm 10.3 MUC2 NKX2-1
8 brachyolmia 10.3 EGFR NKX2-1
9 ovarian large-cell neuroendocrine carcinoma 10.3 EGFR NKX2-1
10 parachordoma 10.3 KRAS NKX2-1
11 breast signet ring cell adenocarcinoma 10.3 EGFR MUC2
12 bladder benign neoplasm 10.3 KRAS NKX2-1
13 large cell neuroendocrine carcinoma 10.3 EGFR HYAL2
14 mixed type thymoma 10.2 EGFR NKX2-1
15 severe pre-eclampsia 10.2 EGFR KRAS
16 common bile duct disease 10.2 EGFR KRAS
17 spindle epithelial tumor with thymus-like differentiation tumor 10.2 EGFR KRAS
18 occupational dermatitis 10.2 EGFR KRAS
19 gorham's disease 10.2 EGFR KRAS
20 acinar cell cystadenocarcinoma 10.1 KRAS MUC2
21 early congenital syphilis 10.1 EGFR KRAS
22 sebaceous adenocarcinoma 10.1 EGFR KRAS
23 pancreatic somatostatinoma 10.1 EGFR KRAS
24 chronic neutrophilic leukemia 10.1 CDX2 NKX2-1
25 peritoneal serous adenocarcinoma 10.1 KRAS MUC2
26 large cell carcinoma with rhabdoid phenotype 10.1 EGFR NKX2-1
27 endometriosis of uterus 10.0 EGFR KRAS
28 human t-cell leukemia virus type 1 10.0 CDX2 NKX2-1
29 luminal breast carcinoma 10.0 CDX2 EGFR
30 male reproductive organ benign neoplasm 10.0 KRAS MUC2
31 bile duct clear cell adenocarcinoma 10.0 CDX2 MUC2
32 trachea squamous cell carcinoma 10.0 EGFR KRAS
33 breast mucinous cystadenocarcinoma 10.0 CDX2 MUC2
34 cholangitis 10.0 CDX2 MUC2
35 pancreatic serous cystic neoplasm 10.0 EGFR KRAS
36 pyloric antrum cancer 10.0 CDX2 MUC2
37 stricture or kinking of ureter 9.9 CDX2 MUC2
38 intracranial sinus thrombosis 9.9 CDX2 MUC2
39 childhood ovarian endodermal sinus tumor 9.9 CDX2 MUC2
40 prostate small cell carcinoma 9.9 CDX2 MUC2
41 classic variant of chromophobe renal cell carcinoma 9.9 CDX2 MUC2
42 fallopian tube mucinous tumor 9.9 CDX2 EGFR
43 pancreatic signet ring cell adenocarcinoma 9.9 CDX2 MUC2
44 breast mucinous carcinoma 9.9 CDX2 MUC2
45 pericholangitis 9.9 CDX2 MUC2
46 nominal aphasia 9.9 EGFR MUC2
47 bile duct mucinous adenocarcinoma 9.9 CDX2 KRAS
48 microcystic meningioma 9.9 CDX2 MUC2
49 adenocarcinoma in situ 9.9 CDX2 KRAS
50 breast adenoid cystic carcinoma 9.9 EGFR KRAS NKX2-1

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


coughing, dyspnea, fever, hemoptysis

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 CDX2 EGFR KRAS MUC2 NKX2-1
2 growth/size/body region MP:0005378 9.85 CDX2 EGFR HYAL2 KRAS MUC2 NKX2-1
3 digestive/alimentary MP:0005381 9.83 CDX2 EGFR KRAS MUC2 NKX2-1
4 endocrine/exocrine gland MP:0005379 9.8 CDX2 EGFR KRAS MUC2 NKX2-1
5 homeostasis/metabolism MP:0005376 9.8 CDX2 EGFR HYAL2 KRAS MUC2 NKX2-1
6 mortality/aging MP:0010768 9.73 CDX2 EGFR HYAL2 KRAS MUC2 NKX2-1
7 neoplasm MP:0002006 9.55 CDX2 EGFR KRAS MUC2 NKX2-1
8 no phenotypic analysis MP:0003012 9.26 EGFR HYAL2 KRAS NKX2-1
9 skeleton MP:0005390 9.02 CDX2 EGFR HYAL2 KRAS NKX2-1

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
3
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1 33069-62-4 36314
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
7
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
8
Etoposide Approved Phase 3,Phase 1 33419-42-0 36462
9
Lenograstim Approved Phase 3,Phase 2 135968-09-1
10
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
11
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
14
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
15
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
16 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
17 Albumin-Bound Paclitaxel Phase 2, Phase 3, Phase 1
18 Angiogenesis Inhibitors Phase 2, Phase 3, Phase 1
19 Angiogenesis Modulating Agents Phase 2, Phase 3, Phase 1
20 Antimitotic Agents Phase 2, Phase 3, Phase 1
21 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
22 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Antimetabolites Phase 3,Phase 2,Phase 1
27 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
28 Antiviral Agents Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antibodies Phase 2, Phase 3,Phase 1
31 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
32 Immunoglobulins Phase 2, Phase 3,Phase 1
33 Etoposide phosphate Phase 3,Phase 1
34 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
35 Mitogens Phase 3,Phase 2
36 Epoetin alfa Phase 3 113427-24-0
37 Hematinics Phase 3,Phase 2
38 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
39 Folate Nutraceutical Phase 3,Phase 2,Phase 1
40 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
43
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
44
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
45
Promethazine Approved Phase 2 60-87-7 4927
46
Vinblastine Approved Phase 2,Phase 1 865-21-4 13342 241903
47
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
48
Lomustine Approved Phase 2 13010-47-4 3950
49
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
50
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394

Interventional clinical trials:

(show top 50) (show all 101)

id Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
6 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
7 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
8 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
9 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer Unknown status NCT00003494 Phase 2 antineoplaston A10;antineoplaston AS2-1
17 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
18 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
19 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Unknown status NCT00234052 Phase 2 carboplatin;pemetrexed
20 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
21 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
22 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
23 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
24 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
25 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
26 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
27 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
28 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
29 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
30 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
31 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
32 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
33 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
34 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
35 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
36 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
37 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
38 Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00425646 Phase 2 imatinib mesylate
39 Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
40 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
41 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
42 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride
43 Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
44 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00117962 Phase 2 carboplatin;pemetrexed disodium
45 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
46 Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00081302 Phase 2 carboplatin;paclitaxel
47 Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed NCT00033553 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
48 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
49 Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature Completed NCT00198380 Phase 2 Gefitinib
50 Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

MalaCards organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

39
Lung, Brain, Testes, Heart

Publications for Bronchiolo-Alveolar Adenocarcinoma

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

id Title Authors Year
1
Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes. ( 11259097 )
2001
2
Primary bronchiolo-alveolar adenocarcinoma in a dromedary camel (Camelus dromedarius). ( 9549871 )
1998
3
Primary bronchiolo-alveolar adenocarcinoma in a bull. ( 8677609 )
1996
4
Bronchiolo-alveolar adenocarcinoma in a horse. ( 2562160 )
1989
5
Bronchiolo-alveolar adenocarcinoma with multiple cysts. ( 6287799 )
1982

Variations for Bronchiolo-Alveolar Adenocarcinoma

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

9 (show top 50) (show all 1867)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 11
2 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 11
3 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 11
4 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 11
5 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 11
6 COSM49006 YES1 lung,NS,carcinoma,adenocarcinoma c.371+1G>T p.? 11
7 COSM48846 YES1 lung,NS,carcinoma,adenocarcinoma c.473G>T p.W158L 11
8 COSM94103 YBX3 lung,NS,carcinoma,adenocarcinoma c.655G>C p.A219P 11
9 COSM95540 WWP2 lung,NS,carcinoma,adenocarcinoma c.2280G>T p.W760C 11
10 COSM95537 WWP1 lung,NS,carcinoma,adenocarcinoma c.2098G>A p.D700N 11
11 COSM48844 WT1 lung,NS,carcinoma,adenocarcinoma c.668G>C p.S223T 11
12 COSM96290 WNT3 lung,NS,carcinoma,adenocarcinoma c.159C>A p.P53P 11
13 COSM96287 WNT16 lung,NS,carcinoma,adenocarcinoma c.156G>T p.L52L 11
14 COSM95520 WNT10A lung,NS,carcinoma,adenocarcinoma c.217G>A p.E73K 11
15 COSM95518 WNK2 lung,NS,carcinoma,adenocarcinoma c.1349C>A p.A450E 11
16 COSM95689 WNK1 lung,NS,carcinoma,adenocarcinoma c.3218C>G p.S1073* 11
17 COSM17658 VHL lung,NS,carcinoma,adenocarcinoma c.286C>T p.Q96* 11
18 COSM5369853 VHL lung,NS,carcinoma,adenocarcinoma c.514C>T p.P172S 11
19 COSM48841 VAV3 lung,NS,carcinoma,adenocarcinoma c.1852C>G p.Q618E 11
20 COSM48840 VAV3 lung,NS,carcinoma,adenocarcinoma c.2519C>A p.S840Y 11
21 COSM48839 VAV2 lung,NS,carcinoma,adenocarcinoma c.301G>T p.D101Y 11
22 COSM48838 VAV2 lung,NS,carcinoma,adenocarcinoma c.428G>T p.R143L 11
23 COSM48837 VAV1 lung,NS,carcinoma,adenocarcinoma c.2402T>C p.L801P 11
24 COSM95504 VAV1 lung,NS,carcinoma,adenocarcinoma c.1551C>A p.D517E 11
25 COSM48836 VAV1 lung,NS,carcinoma,adenocarcinoma c.175G>A p.E59K 11
26 COSM95743 USP4 lung,NS,carcinoma,adenocarcinoma c.2645-1G>C p.? 11
27 COSM95460 USP33 lung,NS,carcinoma,adenocarcinoma c.1219A>G p.R407G 11
28 COSM95461 USP33 lung,NS,carcinoma,adenocarcinoma c.1151A>G p.D384G 11
29 COSM95456 USP31 lung,NS,carcinoma,adenocarcinoma c.1681G>T p.D561Y 11
30 COSM96263 USP22 lung,NS,carcinoma,adenocarcinoma c.1399C>T p.L467L 11
31 COSM96261 USP20 lung,NS,carcinoma,adenocarcinoma c.477C>T p.A159A 11
32 COSM95684 USP19 lung,NS,carcinoma,adenocarcinoma c.1190C>G p.S397* 11
33 COSM94157 UBR5 lung,NS,carcinoma,adenocarcinoma c.3368G>T p.G1123V 11
34 COSM94156 UBR5 lung,NS,carcinoma,adenocarcinoma c.3554G>T p.G1185V 11
35 COSM94154 UBR5 lung,NS,carcinoma,adenocarcinoma c.4739G>T p.G1580V 11
36 COSM95839 UBR5 lung,NS,carcinoma,adenocarcinoma c.8328C>G p.L2776L 11
37 COSM48833 TYK2 lung,NS,carcinoma,adenocarcinoma c.3545C>T p.S1182L 11
38 COSM48834 TYK2 lung,NS,carcinoma,adenocarcinoma c.3206C>G p.A1069G 11
39 COSM95422 TYK2 lung,NS,carcinoma,adenocarcinoma c.1181G>A p.S394N 11
40 COSM95418 TTK lung,NS,carcinoma,adenocarcinoma c.2245G>T p.D749Y 11
41 COSM48829 TSHR lung,NS,carcinoma,adenocarcinoma c.18G>T p.L6F 11
42 COSM48830 TSHR lung,NS,carcinoma,adenocarcinoma c.1555C>A p.R519S 11
43 COSM48831 TSHR lung,NS,carcinoma,adenocarcinoma c.1966G>A p.V656I 11
44 COSM48827 TSC2 lung,NS,carcinoma,adenocarcinoma c.1923C>A p.S641R 11
45 COSM48826 TSC2 lung,NS,carcinoma,adenocarcinoma c.1414G>A p.V472M 11
46 COSM48828 TSC2 lung,NS,carcinoma,adenocarcinoma c.3867G>T p.R1289S 11
47 COSM95412 TSC1 lung,NS,carcinoma,adenocarcinoma c.193C>G p.Q65E 11
48 COSM48825 TSC1 lung,NS,carcinoma,adenocarcinoma c.611G>T p.R204L 11
49 COSM95403 TRIM33 lung,NS,carcinoma,adenocarcinoma c.1812G>T p.R604S 11
50 COSM95404 TRIM33 lung,NS,carcinoma,adenocarcinoma c.379G>A p.V127M 11

Expression for Bronchiolo-Alveolar Adenocarcinoma

Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.

Pathways for Bronchiolo-Alveolar Adenocarcinoma

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

Cellular components related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 8.96 EGFR HYAL2
2 membrane raft GO:0045121 8.8 EGFR HYAL2 KRAS

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 9.4 EGFR HYAL2
2 positive regulation of MAP kinase activity GO:0043406 9.37 EGFR KRAS
3 epidermal growth factor receptor signaling pathway GO:0007173 9.32 EGFR KRAS
4 pattern specification process GO:0007389 9.26 CDX2 NKX2-1
5 ERBB2 signaling pathway GO:0038128 9.16 EGFR KRAS
6 epithelial tube branching involved in lung morphogenesis GO:0060441 8.96 KRAS NKX2-1
7 cerebral cortex cell migration GO:0021795 8.62 EGFR NKX2-1

Molecular functions related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 8.8 EGFR HYAL2 NKX2-1
2 virus receptor activity GO:0001618 8.65 HYAL2

Sources for Bronchiolo-Alveolar Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....